CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, we confirmed that BCR-ABL inhibition is partial in chronic phase-CML CD34+ cells that accumulated a significant amount of nilotinib, suggesting a lower targeting efficacy of nilotinib in this subset through yet unknown mechanisms.